GlassScriptPhysician profile
Chun Wang Y Tan
NPI 1104825785
$13,111.92
in general payments reported to CMS, 2019-2025
26 companies · $3,653 in 2025
The $3,653 reported for 2025 was more than what 90% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,717 · 2020: $224 · 2021: $648 · 2022: $751 · 2023: $1,989 · 2024: $4,131 · 2025: $3,653.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,581 · Travel and Lodging: $3,004 · Education: $188.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,580.78 |
| Travel and Lodging | $3,004.08 |
| Education | $187.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $5,562.44 | 2021-2025 | Micra, Azure Xt Dr Mri Surescan, Cobalt Dr Mri Surescan |
| Actelion Pharmaceuticals US, INC. | $1,072.60 | 2019-2025 | Uptravi, Opsumit |
| E.R. Squibb & Sons, L.L.C. | $949.61 | 2019-2025 | Camzyos, Eliquis |
| Medtronic Vascular, INC. | $889.18 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $845.32 | 2019-2024 | Xarelto |
| Merck Sharp & Dohme LLC | $695.31 | 2021-2025 | Verquvo, Capvaxive |
| Amgen INC. | $430.29 | 2019-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $383.10 | 2019-2025 | |
| Pfizer INC. | $379.26 | 2019-2025 | |
| Cvrx, INC. | $373.30 | 2023-2025 | Barostim Neo System |
| Astrazeneca Pharmaceuticals LP | $252.14 | 2020-2025 | Farxiga |
| Alnylam Pharmaceuticals INC. | $213.56 | 2023-2025 | Onpattro, Amvuttra |
| Abiomed | $212.74 | 2023 | Impella |
| Abbott Laboratories | $192.69 | 2020-2025 | Aveir |
| Cardiovascular Systems INC. | $120.49 | 2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inari Medical, INC. | $100.22 | 2023 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $85.19 | 2019-2024 | Lifevest |
| Scpharmaceuticals INC. | $79.15 | 2023-2025 | |
| Esperion Therapeutics, INC. | $67.76 | 2021-2025 | Nexletol |
| Kiniksa Pharmaceuticals, LTD. | $46.49 | 2022-2023 | Arcalyst |
| Edwards Lifesciences Corporation | $37.53 | 2025 | Sapien 3 Ultra Resilia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $37.14 | 2025 | Jardiance |
| Acist Medical Systems, INC. | $32.00 | 2021 | |
| Boston Scientific Corporation | $24.50 | 2025 | Watchman Flx |
| Lexicon Pharmaceuticals, INC. | $16.34 | 2023 | Inpefa |
| Glaxosmithkline, LLC. | $13.57 | 2025 | Arexvy, Shingrix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chun Wang Tan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.